M
Margarete Focke-Tejkl
Researcher at Medical University of Vienna
Publications - 78
Citations - 2715
Margarete Focke-Tejkl is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Immunoglobulin E & Allergen. The author has an hindex of 31, co-authored 75 publications receiving 2296 citations. Previous affiliations of Margarete Focke-Tejkl include University of Vienna & University of Health Sciences Antigua.
Papers
More filters
Journal ArticleDOI
From Allergen Genes to Allergy Vaccines
Rudolf Valenta,Fatima Ferreira,Margarete Focke-Tejkl,Birgit Linhart,Verena Niederberger,Ines Swoboda,Susanne Vrtala +6 more
TL;DR: Various types of allergy vaccines that have been developed based on allergen structures, results from their clinical application in allergic patients, and future strategies for allerGEN-specific immunotherapy and allergy prophylaxis are reviewed.
Journal ArticleDOI
B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines.
Charlotte Admyre,Barbara Bohle,Sara M. Johansson,Margarete Focke-Tejkl,Rudolf Valenta,Annika Scheynius,Susanne Gabrielsson +6 more
TL;DR: It is demonstrated for the first time that exosomes isolated from B cells can present allergen-derived peptides and thereby induce T-cell proliferation and T(H)2-like cytokine production and the data suggest thatExosomes from B lymphocytes are an immunostimulatory factor in allergic immune responses.
Journal ArticleDOI
Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin
TL;DR: Experiments with sera from allergic patients suggest that glycomodified human transferrin, especially the MMXF glycoform, is a suitable reagent for the detection of antibodies against cross-reactive carbohydrate determinants.
Journal ArticleDOI
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
Margarete Focke-Tejkl,Milena Weber,Katarzyna Niespodziana,Angela Neubauer,Hans Huber,Rainer Henning,Gottfried Stegfellner,Bernhard Maderegger,Martina Hauer,Frank Stolz,Verena Niederberger,Katharina Marth,Julia Eckl-Dorna,Richard Weiss,Josef Thalhamer,Katharina Blatt,Peter Valent,Rudolf Valenta +17 more
TL;DR: A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergies.
Journal ArticleDOI
Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy
Petra Zieglmayer,Margarete Focke-Tejkl,René Schmutz,Patrick Lemell,René Zieglmayer,Milena Weber,Renata Kiss,Katharina Blatt,Peter Valent,Frank Stolz,Hans Huber,Angela Neubauer,Anette Knoll,Friedrich Horak,Rainer Henning,Rudolf Valenta +15 more
TL;DR: The B cell epitope-based recombinant grass pollen allergy vaccine BM32 is well tolerated and few doses are sufficient to suppress immediate allergic reactions as well as allergen-specific T cell responses via a selective induction of allerGEN-specific IgG antibodies.